Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
OMER 
Omeros Corporation (OMER)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/12/2025: OMER (3-star) is a REGULAR-BUY. BUY since 67 days. Simulated Profits (66.43%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $28
1 Year Target Price $28
| 1 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 133.5% | Avg. Invested days 34 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/12/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 468.90M USD | Price to earnings Ratio - | 1Y Target Price 28 |
Price to earnings Ratio - | 1Y Target Price 28 | ||
Volume (30-day avg) 4 | Beta 2.52 | 52 Weeks Range 2.95 - 13.60 | Updated Date 11/12/2025 |
52 Weeks Range 2.95 - 13.60 | Updated Date 11/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.36 |
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.4475 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.06% | Return on Equity (TTM) -576.33% |
Valuation
Trailing PE - | Forward PE 6.4 | Enterprise Value 623813082 | Price to Sales(TTM) 4.93 |
Enterprise Value 623813082 | Price to Sales(TTM) 4.93 | ||
Enterprise Value to Revenue 8.26 | Enterprise Value to EBITDA -1.49 | Shares Outstanding 68055826 | Shares Floating 65356051 |
Shares Outstanding 68055826 | Shares Floating 65356051 | ||
Percent Insiders 2.9 | Percent Institutions 43.9 |
Upturn AI SWOT
Omeros Corporation
Company Overview
History and Background
Omeros Corporation was founded in 1994. It is a biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for both complement-mediated diseases and disorders of the central nervous system.
Core Business Areas
- Complement-Mediated Diseases: Development and commercialization of therapeutics targeting the complement system, a part of the immune system.
- Central Nervous System Disorders: Development of therapeutics for disorders affecting the brain and nervous system.
Leadership and Structure
Gregory A. Demopulos, M.D. is the Chairman and CEO. The organizational structure is typical for a biotech company, with research, development, and commercial operations.
Top Products and Market Share
Key Offerings
- Omlonti (midazolam) Injection: Omlonti is an IV anesthetic, sedative, and anticonvulsant approved for short surgical procedures, competes with generic midazolam. Omeros reported Q1 2024 OMIDRIA net product revenue of $4.4 million. Competitors include generic versions of midazolam.
- Narsoplimab (OMS721): Narsoplimab is an investigational therapy targeting mannan-binding lectin-associated serine protease-2 (MASP-2) in various complement-mediated diseases, including hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Subject to regulatory approval; no market share yet, and competitors would depend on the specific indication and approved therapies (e.g., eculizumab for atypical hemolytic uremic syndrome).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and characterized by rapid technological advancements, intense research and development efforts, and strict regulatory oversight.
Positioning
Omeros is a mid-sized player focusing on niche areas within complement-mediated diseases and CNS disorders. Their competitive advantage lies in their MASP-2 inhibitor technology.
Total Addressable Market (TAM)
The TAM for complement-mediated diseases is substantial and growing. Omeros is positioned to capture a portion of this market with its MASP-2 inhibitor if approved.
Upturn SWOT Analysis
Strengths
- Proprietary MASP-2 inhibitor technology
- Pipeline of potential therapeutics
- Experienced management team
Weaknesses
- Reliance on regulatory approvals
- Limited commercial infrastructure
- Financial instability
Opportunities
- Expanding indications for narsoplimab
- Partnerships with larger pharmaceutical companies
- Acquisition by a larger company
Threats
- Regulatory setbacks
- Competition from established players
- Patent expirations
- Failure to successfully commercialize products
Competitors and Market Share
Key Competitors
- ALNY
- REGN
- VRTX
Competitive Landscape
Omeros faces stiff competition from larger, more established companies with greater resources. Their success depends on the differentiation and efficacy of their products.
Growth Trajectory and Initiatives
Historical Growth: The historical growth has been volatile, largely dependent on clinical trial outcomes and regulatory decisions.
Future Projections: Future projections depend on the approval and commercialization of narsoplimab.
Recent Initiatives: Focusing on commercializing OMIDRIA and advancing narsoplimab through clinical trials.
Summary
Omeros is a biopharmaceutical company with promising technology but faces significant challenges. Their success hinges on the approval and commercialization of narsoplimab. Omeros' lack of financial stability is concerning. They must manage regulatory risks and competition carefully to succeed.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Omeros Corporation Website
- SEC Filings
- Yahoo Finance
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Omeros Corporation
Exchange NASDAQ | Headquaters Seattle, WA, United States | ||
IPO Launch date 2009-10-08 | Co-Founder, Chairman, CEO & President Dr. Gregory A. Demopulos M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 202 | Website https://www.omeros.com |
Full time employees 202 | Website https://www.omeros.com | ||
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.